ABSTRACT
Ovarian endometrial cysts cause some kinds of ovarian cancer, and iron is considered as one factor of carcinogenesis. In contrast, hypoxia is associated with progression, angiogenesis, metastasis, and resistance to therapy in cancer. We investigated hypoxia-induced perturbation of iron homeostasis in terms of labile iron, iron deposition, and iron regulatory protein (IRP) in ovarian endometrial cysts. Iron deposition, expression of IRPs, and a protein marker of hypoxia in human ovarian endometrial cysts were analyzed histologically. The concentration of free iron and the pO2 level of the cyst fluid of human ovarian cysts (n = 9) were measured. The expression of IRP2 under hypoxia was investigated in vitro by using Ishikawa cells as a model of endometrial cells. Iron deposition and the expression of IRP2 and Carbonic anhydrase 9 (CA9) were strong in endometrial stromal cells in the human ovarian endometrial cysts. The average concentration of free iron in the cyst fluid was 8.1 ± 2.9 mg/L, and the pO2 was 22.4 ± 5.2 mmHg. A cell-based study using Ishikawa cells revealed that IRP2 expression was decreased by an overload of Fe(II) under normoxia but remained unchanged under hypoxia even in the presence of excess Fe(II). An increase in the expression of IRP2 caused upregulation of intracellular iron as a result of the response to iron deficiency, whereas the protein was degraded under iron-rich conditions. We found that iron-rich regions existed in ovarian endometrial cysts concomitantly with the high level of IRP2 expression, which should generally be decomposed upon an overload of iron. We revealed that an insufficient level of oxygen in the cysts is the main factor for the unusual stabilization of IRP2 against iron-mediated degradation, which provides aberrant uptake of iron in ovarian endometrial stromal cells and can potentially lead to carcinogenesis.
Subject(s)
Endometrium/metabolism , Iron Regulatory Protein 2/metabolism , Ovarian Cysts/metabolism , Female , Humans , Hypoxia/metabolism , Iron/metabolism , Iron Regulatory Protein 2/biosynthesis , Tumor Cells, CulturedABSTRACT
Inactivation of the TCA cycle enzyme, fumarate hydratase (FH), drives a metabolic shift to aerobic glycolysis in FH-deficient kidney tumors and cell lines from patients with hereditary leiomyomatosis renal cell cancer (HLRCC), resulting in decreased levels of AMP-activated kinase (AMPK) and p53 tumor suppressor, and activation of the anabolic factors, acetyl-CoA carboxylase and ribosomal protein S6. Reduced AMPK levels lead to diminished expression of the DMT1 iron transporter, and the resulting cytosolic iron deficiency activates the iron regulatory proteins, IRP1 and IRP2, and increases expression of the hypoxia inducible factor HIF-1α, but not HIF-2α. Silencing of HIF-1α or activation of AMPK diminishes invasive activities, indicating that alterations of HIF-1α and AMPK contribute to the oncogenic growth of FH-deficient cells.
Subject(s)
AMP-Activated Protein Kinases/metabolism , Fumarate Hydratase/deficiency , Iron Deficiencies , Kidney Neoplasms/metabolism , Leiomyomatosis/congenital , Acetyl Coenzyme A/biosynthesis , Acetyl-CoA Carboxylase/biosynthesis , Acetyl-CoA Carboxylase/metabolism , Animals , Basic Helix-Loop-Helix Transcription Factors/biosynthesis , Cation Transport Proteins/biosynthesis , Cell Line, Tumor , Fumarate Hydratase/metabolism , Glycolysis/drug effects , Humans , Hypoxia-Inducible Factor 1, alpha Subunit/biosynthesis , Hypoxia-Inducible Factor 1, alpha Subunit/genetics , Iron Regulatory Protein 1/biosynthesis , Iron Regulatory Protein 1/metabolism , Iron Regulatory Protein 2/biosynthesis , Iron Regulatory Protein 2/metabolism , Kidney Neoplasms/enzymology , Kidney Neoplasms/pathology , Leiomyomatosis/metabolism , Leiomyomatosis/pathology , Mice , NADP/biosynthesis , Neoplastic Syndromes, Hereditary , Ribose/biosynthesis , Ribosomal Protein S6/biosynthesis , Ribosomal Protein S6/metabolism , Skin Neoplasms , Thenoyltrifluoroacetone/pharmacology , Tumor Suppressor Protein p53/biosynthesis , Uterine NeoplasmsSubject(s)
Gene Expression Regulation/physiology , Iron/metabolism , Macrophage Activation/physiology , Macrophages/metabolism , Animals , Apoferritins/biosynthesis , Apoferritins/immunology , Cation Transport Proteins/biosynthesis , Cation Transport Proteins/immunology , Gene Expression Regulation/drug effects , Inflammation/immunology , Inflammation/metabolism , Interferon-gamma/immunology , Interferon-gamma/metabolism , Interferon-gamma/pharmacology , Interleukin-4/immunology , Interleukin-4/metabolism , Interleukin-4/pharmacology , Iron/immunology , Iron Regulatory Protein 1/biosynthesis , Iron Regulatory Protein 1/immunology , Iron Regulatory Protein 2/biosynthesis , Iron Regulatory Protein 2/immunology , Lymphocyte Activation/drug effects , Lymphocyte Activation/physiology , Macrophage Activation/drug effects , Macrophages/cytology , Macrophages/immunology , Mice , Receptors, Transferrin/biosynthesis , Receptors, Transferrin/immunology , T-Lymphocytes/cytology , T-Lymphocytes/immunology , T-Lymphocytes/metabolismABSTRACT
BACKGROUND: Macrophages play a key role in iron homeostasis. In peripheral tissues, they are known to polarize into classically activated (or M1) macrophages and alternatively activated (or M2) macrophages. Little is known on whether the polarization program influences the ability of macrophages to store or recycle iron and the molecular machinery involved in the processes. DESIGN AND METHODS: Inflammatory/M1 and alternatively activated/M2 macrophages were propagated in vitro from mouse bone-marrow precursors and polarized in the presence of recombinant interferon-γ or interleukin-4. We characterized and compared their ability to handle radioactive iron, the characteristics of the intracellular iron pools and the expression of molecules involved in internalization, storage and export of the metal. Moreover we verified the influence of iron on the relative ability of polarized macrophages to activate antigen-specific T cells. RESULTS: M1 macrophages have low iron regulatory protein 1 and 2 binding activity, express high levels of ferritin H, low levels of transferrin receptor 1 and internalize--albeit with low efficiency -iron only when its extracellular concentration is high. In contrast, M2 macrophages have high iron regulatory protein binding activity, express low levels of ferritin H and high levels of transferrin receptor 1. M2 macrophages have a larger intracellular labile iron pool, effectively take up and spontaneously release iron at low concentrations and have limited storage ability. Iron export correlates with the expression of ferroportin, which is higher in M2 macrophages. M1 and M2 cells activate antigen-specific, MHC class II-restricted T cells. In the absence of the metal, only M1 macrophages are effective. CONCLUSIONS: Cytokines that drive macrophage polarization ultimately control iron handling, leading to the differentiation of macrophages into a subset which has a relatively sealed intracellular iron content (M1) or into a subset endowed with the ability to recycle the metal (M2).
Subject(s)
Gene Expression Regulation/physiology , Iron/metabolism , Macrophage Activation/physiology , Macrophages/metabolism , Animals , Apoferritins/biosynthesis , Apoferritins/immunology , Cation Transport Proteins/biosynthesis , Cation Transport Proteins/immunology , Gene Expression Regulation/drug effects , Inflammation/immunology , Inflammation/metabolism , Interferon-gamma/immunology , Interferon-gamma/metabolism , Interferon-gamma/pharmacology , Interleukin-4/immunology , Interleukin-4/metabolism , Interleukin-4/pharmacology , Iron/immunology , Iron Regulatory Protein 1/biosynthesis , Iron Regulatory Protein 1/immunology , Iron Regulatory Protein 2/biosynthesis , Iron Regulatory Protein 2/immunology , Lymphocyte Activation/drug effects , Lymphocyte Activation/physiology , Macrophage Activation/drug effects , Macrophages/cytology , Macrophages/immunology , Mice , Receptors, Transferrin/biosynthesis , Receptors, Transferrin/immunology , T-Lymphocytes/cytology , T-Lymphocytes/immunology , T-Lymphocytes/metabolismABSTRACT
Chlamydia trachomatis (CT) is the leading cause of diseases related to reproductive health and iron plays important role in chlamydial pathogenesis. Iron homeostasis in chlamydia-infected cells is not clear thus far. This study shows that expression of the transferrin receptor (TfR) is downregulated, whereas expression of the ferritin heavy chain is upregulated in CT-infected HeLa-229 cells. Expression of iron-regulatory protein (IRP)-1 predominates over IRP-2 in infected cells. In infected cells, attenuated binding activity of IRP-iron responsive elements (IREs) is observed using the electrophoretic mobility-shift assay. These results suggest that iron homeostasis is modulated in CT-infected HeLa cells at the interface of acquisition and commensal use of iron.
Subject(s)
Chlamydia Infections/metabolism , Chlamydia trachomatis/metabolism , Iron Regulatory Protein 1/metabolism , Iron/metabolism , Analysis of Variance , Apoferritins/biosynthesis , Apoferritins/genetics , Apoferritins/metabolism , Chlamydia Infections/genetics , Down-Regulation , HeLa Cells , Humans , Iron Regulatory Protein 1/biosynthesis , Iron Regulatory Protein 1/genetics , Iron Regulatory Protein 2/biosynthesis , Iron Regulatory Protein 2/genetics , Iron Regulatory Protein 2/metabolism , Protein Binding , Receptors, Transferrin/biosynthesis , Receptors, Transferrin/genetics , Receptors, Transferrin/metabolism , Response Elements , Up-RegulationABSTRACT
In a recent study we have explored TfR2 expression in a panel of cancer cell lines and we observed that about 40% of these cell lines clearly express TfR2. Taking advantage of this observation and considering the frequent overexpression of c-Myc in cancer cells we have explored the existence of a possible relationship between c-Myc and TfR2 in these cell lines. Our results provided evidence that TfR2(+) cell lines express low c-Myc levels and low TfR1 levels, while TfR2(-) cell lines express high c-Myc and TfR1 levels. Using the erythroleukemic K562 TfR2(+) cells as a model, we observed that agents that enhance c-Myc expression, such as iron, determine a decrease of TfR2 expression, while molecules that induce a decreased c-Myc expression, such as the iron chelator desferoxamine or the kinase inhibitor ST 1571, induce an enhanced TfR2 expression. On the other hand, we have evaluated a possible effect of hypoxia and nitric oxide on TfR2 expression in erythroleukemia K526 and hepatoma HepG2 cells, providing evidence that: (i) agents inducing cellular hypoxia, such as CoCl(2), elicited a marked upmodulation of TfR1, but a downmodulation of TfR2 expression; (ii) NO(+) donors, such as sodium nitroprusside (SNP), induced a moderate decrease of TfR1, associated with a marked decline of TfR2 expression; (iii) NO donors, such as S-Nitroso-N-Acetylpenicillamine (SNAP), induced a clear increase of TfR1, associated with a moderate upmodulation of TfR2 expression. The ensemble of these observations suggests that in cancer cell lines TfR2 expression can be modulated through stimuli similar to those known to act on TfR1 and these findings may have important implications for our understanding of the role of TfR2 in the regulation of iron homeostasis.
Subject(s)
Antigens, CD/biosynthesis , Proto-Oncogene Proteins c-myc/metabolism , Receptors, Transferrin/biosynthesis , Antigens, CD/drug effects , Antimutagenic Agents/pharmacology , Apoferritins/biosynthesis , Benzamides , Cell Hypoxia/drug effects , Cell Hypoxia/physiology , Cell Line, Tumor , Cobalt/pharmacology , Deferoxamine/pharmacology , Humans , Imatinib Mesylate , Iron/pharmacology , Iron Regulatory Protein 2/biosynthesis , Nitric Oxide/metabolism , Nitric Oxide Donors/pharmacology , Nitroprusside/pharmacology , Penicillamine/analogs & derivatives , Penicillamine/pharmacology , Piperazines , Proto-Oncogene Proteins c-myc/drug effects , Pyrimidines/pharmacology , Receptors, Transferrin/drug effects , Siderophores/pharmacologyABSTRACT
One consequence of zinc deficiency is an elevation in cell and tissue iron concentrations. To examine the mechanism(s) underlying this phenomenon, Swiss 3T3 cells were cultured in zinc-deficient (D, 0.5 microM zinc), zinc-supplemented (S, 50 microM zinc), or control (C, 4 microM zinc) media. After 24 h of culture, cells in the D group were characterized by a 50% decrease in intracellular zinc and a 35% increase in intracellular iron relative to cells in the S and C groups. The increase in cellular iron was associated with increased transferrin receptor 1 protein and mRNA levels and increased ferritin light chain expression. The divalent metal transporter 1(+)iron-responsive element isoform mRNA was decreased during zinc deficiency-induced iron accumulation. Examination of zinc-deficient cells revealed increased binding of iron regulatory protein 2 (IRP2) and decreased binding of IRP1 to a consensus iron-responsive element. The increased IRP2-binding activity in zinc-deficient cells coincided with an increased level of IRP2 protein. The accumulation of IRP2 protein was independent of zinc deficiency-induced intracellular nitric oxide production but was attenuated by the addition of the antioxidant N-acetylcysteine or ascorbate to the D medium. These data support the concept that zinc deficiency can result in alterations in iron transporter, storage, and regulatory proteins, which facilitate iron accumulation.
Subject(s)
Gene Expression Regulation/physiology , Iron/metabolism , Zinc/deficiency , 3T3 Cells , Acetylcysteine/pharmacology , Animals , Antioxidants/pharmacology , Apoferritins/biosynthesis , Ascorbic Acid/pharmacology , Gene Expression Regulation/drug effects , Iron Regulatory Protein 1/biosynthesis , Iron Regulatory Protein 2/biosynthesis , Mice , Nitric Oxide/metabolism , RNA, Messenger/biosynthesis , Receptors, Transferrin/biosynthesis , Response Elements/physiologyABSTRACT
Accumulating evidence implicates a role for altered iron and copper metabolism in the pathogenesis of neurodegenerative disorders such as Alzheimer's disease (AD). However, imbalances in the levels of the various forms of iron at different stages of AD have not been examined. In this pilot study we extracted and measured the levels of loosely bound, non-heme and total iron and copper in the frontal cortex and hippocampus of patients with mild-moderate AD (n=3), severe AD (n=8) and dementia with Lewy bodies (DLB, n=6), using graphite furnace atomic absorption spectrometry (GFAAS). Additionally, the expression of iron regulatory protein 2 (IRP2) was examined in relation to the pathological hallmarks of AD and DLB, amyloid plaques, neurofibrillary tangles (NFT), and Lewy bodies, by immunohistochemistry. We found significantly decreased loosely bound iron in the hippocampal white matter of mild-moderate and severe AD patients and a trend towards increased non-heme iron in the hippocampal gray matter of severe AD patients. Furthermore, decreased levels of total copper were seen in severe AD and DLB frontal cortex compared to controls, suggesting an imbalance in brain metal levels in both AD and DLB. The decrease in loosely bound iron in mild-moderate AD patients may be associated with myelin breakdown seen in the beginning stages of AD and implicates that iron dysregulation is an early event in AD pathogenesis.
Subject(s)
Alzheimer Disease/pathology , Brain Chemistry , Copper/analysis , Iron Regulatory Protein 2/biosynthesis , Iron/analysis , Lewy Body Disease/pathology , Aged , Aged, 80 and over , Alzheimer Disease/etiology , Female , Humans , Immunohistochemistry , Lewy Bodies/chemistry , Lewy Body Disease/etiology , Male , Middle Aged , Neurofibrillary Tangles/chemistry , Plaque, Amyloid/chemistryABSTRACT
BACKGROUND AND OBJECTIVES: The functions of the iron regulatory proteins (IRP1 and IRP2), which control cellular iron homeostasis are similar but not identical. As an inappropriate up-regulation of total IRP activity has been found in the duodenum and monocytes of patients with hereditary hemochromatosis (HH), we investigated the respective roles of IRP1 and IRP2 in these settings. DESIGN AND METHODS: Specific antibodies were used in RNA-supershift, immunoblotting and immunohistochemistry assays to evaluate IRP1 and IRP2 separately in monocytes, macrophages and duodenum of control subjects, and patients with HH or iron-deficiency anemia. RESULTS: The activity of both IRP1 and IRP2 and the levels of IRP2 were: (i) higher in monocytes and macrophages of HH patients than in those of control subjects; (ii) increased in the duodenal samples of the patients with HH and iron-deficiency anemia. IRP2 levels increased when monocytes differentiated to macrophages. Under all of the examined conditions, IRP2 was induced to a greater extent. In the duodenum of HH and anemic patients, IRP1 was shifted from the aconitase form (present in controls) to the apoform, whereas the IRP1 in monocytes/macrophages was always in the apoform, in both the patients and controls. The RNA-bound fraction of IRP1 was small in all of the samples. Both IRP were expressed more in the villi than in the crypts of the duodenum, with no differences in localization or expression between the patients and controls. INTERPRETATION AND CONCLUSIONS: These findings of the first extensive investigation of the comparative expression of the two IRP in human tissues and blood cells indicate that IRP2 is the major regulator of intracellular iron homeostasis in humans.